Last Updated on June 18, 2026 by Staff
Golden staph infections are a deal. They are one of the serious kinds of bacterial infections in the world. Every year they cause more than one million deaths. When the bacteria get into the bloodstream it becomes really dangerous. The death rate can be as high as 15% to 25%. For a time doctors have been using the antibiotic flucloxacillin to treat these infections.
However a big international clinical trial has found that there are safer and effective alternatives.
The findings of this trial could change the way hospitals treat bloodstream infections caused by staph.
Landmark Trial
This discovery comes from a clinical study called the Staphylococcus aureus Network Adaptive Platform Trial or SNAP Trial for short. It is the study ever done on golden staph infections. The trial involved more than 150 hospitals in over 14 countries. It was led by researchers from the Peter Doherty Institute for Infection and Immunity and the University of Newcastle.
The goal of the trial was to figure out which antibiotics work best for patients with bloodstream infections. The researchers compared treatment options to see which ones could reduce deaths, minimize complications and improve recovery.
The results were published in two medical journals, the New England Journal of Medicine and The Lancet.
Cefazolin Advantage
One part of the study looked at methicillin- Staphylococcus aureus or MSSA bloodstream infections. The researchers compared the flucloxacillin with cefazolin.
They found that cefazolin was just as effective as flucloxacillin in treating the infection.. It had fewer side effects and a lower risk of kidney damage.
The study showed that the death rate within 90 days was slightly lower for patients who took cefazolin. 15% Of the patients who took cefazolin died within 90 days compared to 17% of those who took flucloxacillin.
The researchers also found that there were cases of acute kidney injury in the cefazolin group. 14% Of the patients who took cefazolin had kidney problems compared to 20% of those who took flucloxacillin.
These results suggest that cefazolin might be a first-line treatment option for MSSA bloodstream infections.
Penicillin Returns
Another study looked at patients with penicillin- Staphylococcus aureus or PSSA, infections. The researchers wanted to see if benzylpenicillin, one of the antibiotics, could effectively treat these infections when lab tests showed the bacteria were susceptible.
The results were very promising. Benzylpenicillin worked as well as flucloxacillin in controlling the infection and seemed to cause fewer side effects.
Patients who took benzylpenicillin had kidney damage and lower death rates. 14% Of the patients who took benzylpenicillin died, compared to 22% of those who took flucloxacillin.
These findings suggest that older antibiotics can still be useful in medicine if used correctly.
Changing Treatment
The trial’s findings challenge what doctors have been doing for decades. Flucloxacillin became the treatment because many golden staph strains became resistant to penicillin.. Now researchers realize that some strains are still susceptible to penicillin and can be safely treated with alternative antibiotics.
The doctors who worked on the study think the evidence is strong enough to support a change in treatment. They believe that flucloxacillin should not be the default treatment for bloodstream infections caused by golden staph.
This change could reduce treatment-related complications. Improve patient outcomes worldwide.
Future Impact
The researchers think the next challenge is to make sure these findings are used in clinical practice. Hospitals, labs and health organizations will need to update their treatment guidelines to reflect the evidence.
In some countries cefazolin may need to be widely available to support its use. Lab testing will also play a role in identifying patients who can benefit from benzylpenicillin treatment.
The SNAP Trial is a breakthrough in infectious disease research. By finding equally effective antibiotics the study has the potential to save thousands of lives each year and reduce complications associated with treatment.
As antibiotic resistance continues to grow, discoveries like these provide valuable tools in the ongoing fight against dangerous bacterial infections.
Leave a Reply